Endocrine Abstracts

Background: The Glucagon-like peptide-1 receptor agonist (GLP1RA) semaglutide has shown improvements in glycaemia and other metabolic parameters for patients with type 2 diabetes (T2D) in clinical trials. Published real-world data are sparse and there are none from the Middle East where semaglutide became available in 2020.Method and Results: We retrospectively gathered data for 289 patients (median age 50 years (IQR 42-57), 36% female, 87% Emirati and 8...

Background: Tirzepatide is a GLP-1/GIP co-agonist treatment for type 2 diabetes. Participants in the SURPASS trials were GLP-1RA naïve, but in clinical practice many patients are switched from other GLP-1RAs.Aims: To explore effects of prior GLP-1RA treatment on tirzepatide therapy outcomes.Methods: Review of clinical data from an outpatient Diabetes centre. Adults with 6 months follow-up post tirzepatide initiation were inclu...